Andrea Difabio Sells 2,607 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insider Andrea Difabio sold 2,607 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $156,706.77. Following the transaction, the insider directly owned 4,893 shares of the company’s stock, valued at $294,118.23. The trade was a 34.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Xenon Pharmaceuticals Stock Performance

Xenon Pharmaceuticals stock opened at $57.90 on Friday. The company has a market capitalization of $4.82 billion, a PE ratio of -13.28 and a beta of 0.91. Xenon Pharmaceuticals Inc. has a fifty-two week low of $26.74 and a fifty-two week high of $63.95. The firm has a 50 day moving average price of $43.49 and a 200 day moving average price of $41.80.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same period in the prior year, the business posted ($0.84) earnings per share. As a group, equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Trending Headlines about Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Closed upsized offering — Xenon completed an upsized public offering that raised roughly $747.5M (including full exercise of the underwriters’ option), providing substantial cash to fund Phase‑3 activities, NDA planning and early commercial buildout, and materially lowering near‑term financing risk. GlobeNewswire: Closing of Offering
• Positive Sentiment: Clinical derisking — Xenon’s lead candidate azetukalner posted a positive Phase‑3 efficacy readout in focal‑onset seizures and management plans an NDA filing in 2026, which increases the program’s near‑term commercial value and supports upside case assumptions. Zacks: Azetukalner Study
• Positive Sentiment: Analyst support rising — Multiple brokerages raised price targets and maintained buy/overweight stances (examples: Deutsche Bank, HC Wainwright, Wells Fargo), which can attract momentum buyers and institutional interest. Deutsche Bank PT HC Wainwright Note
• Neutral Sentiment: Model updates — HC Wainwright adjusted multi‑year EPS forecasts (improving FY2028–FY2030 but nudging FY2027 worse), reflecting shifting timing/commercial assumptions; useful for modeling but still speculative. HC Wainwright EPS Revision
• Negative Sentiment: Insider selling — CEO Ian Mortimer and several other insiders disclosed large open‑market sales (CEO sold ~270k shares; additional insiders sold smaller blocks), which reduces insider ownership and may concern some investors about timing/liquidity taking. SEC Filing: Insider Sales
• Negative Sentiment: Dilution risk — the large share issuance (and pre‑funded warrants / potential additional option shares) increases outstanding share count and can pressure near‑term per‑share metrics and valuation multiples despite the stronger cash position. GlobeNewswire: Closing of Offering

Hedge Funds Weigh In On Xenon Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC grew its position in shares of Xenon Pharmaceuticals by 0.5% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock worth $243,124,000 after buying an additional 24,444 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Xenon Pharmaceuticals by 3.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,084,034 shares of the biopharmaceutical company’s stock valued at $183,110,000 after acquiring an additional 140,149 shares in the last quarter. Wellington Management Group LLP raised its holdings in Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after acquiring an additional 1,435,096 shares in the last quarter. Braidwell LP lifted its stake in Xenon Pharmaceuticals by 33.0% in the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock worth $112,837,000 after acquiring an additional 895,154 shares during the last quarter. Finally, Capital International Investors grew its holdings in Xenon Pharmaceuticals by 7.3% during the 4th quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock worth $153,058,000 after acquiring an additional 233,466 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Analyst Ratings Changes

XENE has been the subject of a number of research analyst reports. Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday. Stifel Nicolaus set a $66.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 10th. Robert W. Baird raised their price objective on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday. JPMorgan Chase & Co. lifted their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $71.94.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.